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Abstract
It is now generally accepted that CD4+CD25+ Treg cells play a
major role in the prevention of autoimmunity and pathological
immune responses. Their involvement in the pathogenesis of
chronic arthritis is controversial, however, and so we examined
their role in experimental antigen-induced arthritis in mice.
Depletion of CD25-expressing cells in immunized animals
before arthritis induction led to increased cellular and humoral
immune responses to the inducing antigen (methylated bovine
serum albumin; mBSA) and autoantigens, and to an
exacerbation of arthritis, as indicated by clinical (knee joint
swelling) and histological scores. Transfer of CD4+CD25+ cells
into immunized mice at the time of induction of antigen-induced
arthritis decreased the severity of disease but was not able to
cure established arthritis. No significant changes in mBSA-
specific immune responses were detected. In vivo migration
studies showed a preferential accumulation of CD4+CD25+
cells in the inflamed joint as compared with CD4+CD25- cells.
These data imply a significant role for CD4+CD25+ Treg cells in
the control of chronic arthritis. However, transferred Treg cells
appear to be unable to counteract established acute or chronic
inflammation. This is of considerable importance for the timing of
Treg cell transfer in potential therapeutic applications.
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Introduction
Rheumatoid arthritis (RA) is the most common autoimmune
disease in humans, affecting 1% of the population in west-
ern countries. Histologically, RA is characterized by hyper-
plasia and infiltration of the synovial membrane with
mononuclear cells, development of an aggressive tissue
called pannus and secretion of proteases, which are
responsible for the destruction of articular cartilage and
adjacent bone. It is well established that macrophages and
synovial fibroblasts are effector cells of joint destruction,
and it is presumed that autoreactive CD4+ T cells are
involved in their activation [1]. There is now a large body of
evidence that, in rodents, regulatory T cells (Treg) actively
control the activation of autoreactive T cells and thus main-
tain immunological self-tolerance. Apart from adaptive Treg
cells, which can be induced by antigen-specific stimulation
of conventional peripheral T cells under tolerogenic condi-
tions (for review [2]), there is no doubt that naturally occur-
ring Treg cells exist in healthy mice as well as in humans and
rats, and these are characterized by constitutive expression
of CD25 [3-5]. Absence of these cells in vivo results in a
multi-organ autoimmune syndrome [3,6]. These
CD4+CD25+ Treg cells leave the thymus as committed 'pro-
fessional' suppressor T cells [7-9], proliferate in the periph-
ery, and acquire an effector/memory-like phenotype [10]. In
unmanipulated mice, Treg cells can also be found in the
CD25-  compartment, based on the expression of the
AIA = antigen-induced arthritis; CFSE = 5,6-carboxyfluorescein diacetate succinimidyl ester; DTH = delayed-type hypersensitivity; ELISA = enzyme-
linked immunosorbent assay; FACS = fluorescence-activated cell sorting; FCS = fetal calf serum; IFN = interferon; IL = interleukin; mBSA = methyl-
ated bovine serum albumin; PBS = phosphate-buffered saline; RA = rheumatoid arthritis; SCID = severe combined immunodeficient; Treg = regulatory 
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integrin  αEβ7 [10,11], possibly reflecting differences in
developmental stages of these cells.
The exact role played by naturally occurring CD4+CD25+
Treg cells in the pathogenesis of arthritis remains controver-
sial. Arthritis is part of the autoimmune syndrome induced
by transfer of CD25-depleted splenocytes into lympho-
penic hosts [3], and CD4+CD25+ cells are protective in
collagen-induced arthritis [12]. However, Bardos and cow-
orkers [13] ruled out a role for naturally occurring
CD4+CD25+ Treg cells in proteoglycan-induced arthritis.
To clarify this issue, we used the antigen-induced arthritis
(AIA) model. AIA is a Tcell-dependent experimental arthritis
that is induced by intra-articular injection of antigen (meth-
ylated bovine serum albumin [mBSA]) into knee joints of
preimmunized mice [14,15]. This results in an acute inflam-
matory reaction, which is characterized by exudation of
neutrophils and fibrin, which later proceeds to a chronic
arthritis with synovial hyperplasia, infiltration of mononu-
clear cells, and cartilage and bone destruction – his-
topathological changes similar to those that occur in RA.
Autoimmune responses against cartilage constituents such
as collagen types I and II and proteoglycans are involved in
rendering the disease chronic [16,17]. Beyond the 100%
incidence of arthritis, another major advantage of the AIA
model is that the time point of induction of arthritis is
known, allowing manipulation of CD4+CD25+  Treg  cell
number  in vivo at defined stages in the disease. Using
depletion of CD25-expressing cells or transfer of
CD4+CD25+ cells, in the present study we demonstrated
that Treg cells modulate the onset of AIA but are ineffective
at later stages, calling into question their value as a new
therapeutic approach to established chronic arthritis.
Methods
Animals, arthritis induction and assessment
For all animal experiments, female C57Bl/6 mice (Charles
River, Sulzfeld, Germany; age range 6–10 weeks) were
used. Animals were kept under standard conditions, fed a
standard diet and given free access to water. All animal
studies were approved by the government commission for
animal protection.
At 21 and 14 days before arthritis induction, mice were
subcutaneously injected with 100 µg mBSA (Sigma,
Deisenhofen, Germany), emulsified in complete Freund's
adjuvant (Sigma) supplemented to 2 mg/ml heat-killed
Mycobacterium tuberculosis (strain H37RA; Becton Dick-
inson [BD], Heidelberg, Germany). Simultaneously, mice
received 5 × 108 heat-inactivated  Bordetella pertussis
(Chiron-Behring, Marburg, Germany) intraperitoneally.
Arthritis was induced by intra-articular injection of 100 µg
mBSA in 25 µl phosphate-buffered saline (PBS) into the
right knee joint cavity.
Arthritis severity was monitored by measurement of lateral
joint diameter using a vernier caliper (Oditest, Kroeplin Län-
genmesstechnik, Schlüchtern, Germany). Histological
severity of arthritis was scored in a blinded manner by two
investigators (PKP and MG) in frontal knee joint sections,
stained with haematoxylin and eosin and prepared as
described previously [14]. Briefly, at least four sections per
knee joint were semiquantitatively examined on a 0–3 point
scale for each of the following: extent of synovial hyperpla-
sia, mononuclear infiltration, cartilage destruction and pan-
nus formation.
Antibodies and reagents
The following antibodies were grown and purified from the
culture supernatants in our laboratory: anti-CD25 (PC61),
anti-CD3 (145 2C11), anti-CD4-FITC and FITC-labelled
anti-CD4-F(ab) (GK1.5), anti-CD8 (TIB105), anti-CD28
(37.51) and anti-Mac-1 (M1/70). The following antibodies
and secondary reagents were purchased from BD
Pharmingen (Heidelberg, Germany): PE-Cy5-labelled anti-
CD4 (H129.9), biotinylated anti-αEβ7 (M290), biotinylated
anti-CD25 (7D4), allophycocyanine or FITC-conjugated
anti-CD25 (PC61), streptavidin-allophycocyanine and
streptavidin-PE, and matched antibody pairs for ELISPOT
analysis of IFN-γ (R4-6A2 and biotinylated XMG1.2) and IL-
4 (BVD4 1D11 and biotinylated BVD6-24G2) production.
In vivo depletion
Mice were injected with 0.5 mg purified anti-CD25 anti-
body (PC61) 4 and 2 days before intra-articular antigen
injection. Polyclonal rat IgG, purified from normal rat serum,
was used as control. The degree of depletion was deter-
mined by fluorescence-activated cell sorting, using a non-
cross-reactive biotin-labelled anti-CD25, FITC-labelled
anti-CD4 and streptavidin-conjugated  allophycocyanine.
Measurement was performed using FACSCalibur® (BD)
and data were analyzed using WinMDI http://
www.scripps.edu.
Preparation, pre-activation and transfer of regulatory T 
cells
Pooled spleen and lymph node cells from naive C57Bl/6
donors or, if indicated, from immunized mice were incu-
bated with anti-CD4-FITC (clone GK1.5) and anti-CD25-
biotin (clone 7D4; BD). CD4+ T cells were isolated using
an anti-FITC-Multisort-Kit (Miltenyi Biotech, Bergisch-Glad-
bach, Germany) in accordance with the manufacturer's
instructions. CD4+ T cells were sorted into CD25- and
CD25+ cells using anti-biotin MicroBeads (Miltenyi Bio-
tech). Purity was greater than 92% for CD4+CD25- and
greater than 80% for CD4+CD25+ cells.
CD25-expressing and αEβ7-expressing subsets were
sorted by FACS. Briefly, pooled spleen and lymph node
cells from naive mice were stained with anti-CD25-FITC,Available online http://arthritis-research.com/content/7/2/R291
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anti-αEβ7-biotin and streptavidin-PE. The stained cells were
enriched with anti-FITC and anti-PE MicroBeads, using the
AutoMACS separation unit (Miltenyi Biotech). Thereafter,
the cells were sorted into subsets according to their
expression of CD25 or αEβ7 using a FACSDiVa cell sorter
(BD). The purity was 90–95%, as determined by FACS.
For activation, cells were cultured for 24–72 hours in the
presence of plate-bound anti-CD3 (3 µg/ml), anti-CD28
(10 µg/ml) and rhIL-2 (100 U/ml; Chiron, Ratingen, Ger-
many) in RPMI 1640 containing 10% fetal calf serum (FCS;
Gibco, Karlsruhe, Germany). Thereafter, cells were washed
with PBS and transferred intravenously via lateral tail vein
into mice at the time point of AIA induction or at later time
points when indicated.
Delayed-type hypersensitivity reaction
Seven days after arthritis induction, mice were challenged
by intradermal injection into their ears of 5 µg mBSA in 10
µl PBS. Ear thickness was measured before injection and
24 and 48 hours later using a vernier caliper (Kroeplin).
Proliferation assay and ELISPOT analysis
Single cell suspension from spleens and lymph nodes
(inguinal, popliteal, axillary) were cultured at a density of 1
× 106/ml in RPMI 1640, containing 10% FCS, 2 mmol/l L-
glutamine, 10 mmol/l Hepes, 1 mmol/l sodium pyruvate,
0.5 µmol/l 2-mercaptoethanol and antibiotics (100 U/ml
penicillin, 0.1 mg/ml streptomycin; all from Gibco) in the
presence of medium alone or 25 µg/ml mBSA for 72 hours
in 96-well tissue culture plates (Greiner Bio One, Nürtin-
gen, Germany). Cells were pulsed with 0.5 µCi [3H]thymi-
dine (Amersham-Buchler, Braunschweig, Germany) for the
last 18 hours of culture. Thereafter, cells were harvested
onto 96-well glass fibre filters (Packard Bioscience, Gron-
ingen, The Netherlands), and [3H]thymidine incorporation
was measured with a scintillation counter (Top-Count;
Packard Bioscience).
For ELISPOT analysis, PVDF-membrane 96-well micro-
plates (Millipore, Eschborn, Germany) were coated over-
night at 4°C with the primary antibody diluted in sterile
PBS. After washing, plates were blocked for 2 hours with
RPMI 1640 containing 10% FCS. Thereafter 2 × 105 (IL-2
and IFN-γ) or 1 × 106 (IL-4) cells were cultured in duplicate
wells for 24 (IL-2 and IFN-γ) or 48 hours (IL-4). After wash-
ing again plates were incubated overnight at 4°C with the
secondary antibody diluted in PBS/1% BSA. Extravidin–
alkaline phosphatase conjugate (1:30,000 in PBS/1%
BSA) and BCIP/NBT solution (bromochloroindolyle
phophate/nitroblue tetrazolium; both from Sigma) were
used for spot development. The number of spots was quan-
tified using a KS-ELISPOT-Reader (Carl Zeiss, Oberko-
chen, Germany).
Determination of serum IgG by ELISA
Microplates (96-well; Greiner Bio One) were coated with
antigen (0.125 µg/ml mBSA), collagen type I (from rat tail
tendon) and type II (10 µg/ml), and proteoglycans (10 µg/
ml both from bovine cartilage) and left overnight, as
described previously [14]. After washing, plates were incu-
bated with serially diluted serum samples and the amount
of bound IgG was determined using anti-mouse IgG-perox-
idase conjugate (ICN, Eschwege, Germany) and ortho-
phenylendiamine (Sigma) as substrate. Extinction was
measured at 492 nm against 620 nm with an ELISA reader
(Tecan, Crailsheim, Germany).
Cell transfer for in vivo homing assay
For in vivo homing assay, cells were sorted with a modified
protocol and labelled with 111indium, as described else-
where [10]. Briefly, CD4+ cells were enriched by negative
selection. Enriched CD4+ T cells were stained with FITC-
conjugated anti-CD4-F(ab) and anti-CD25-allophycocya-
nine and sorted into CD4+CD25+ or CD4+CD25- cells by
FACS (BD). Cells were labelled with 111In (Indiumoxin;
Amersham-Buchler) for 20 min at room temperature; 1 ×
106 labeled cells were injected intravenously, and 24 hours
later mice were killed and the distribution of radioactivity in
various organs and the rest of the body was measured in a
γ-counter (Wallac Counter, Turku, Finnland).
Alternatively, a proportion of these cells was labelled with
5,6-carboxyfluorescein diacetate succinimidyl ester
(CFSE) by incubation with 5 µmol/l CFSE (Molecular
Probes, Leiden, The Netherlands) in RPMI 1640 for 5 min
at room temperature. After washing, 1 × 106 cells were
injected intravenously. Twenty-four hours later single cell
suspensions were prepared from the draining and nond-
raining peripheral and mesenteric lymph nodes, the spleen
and the peripheral blood, and stained with anti-CD4 and
analyzed by FACS. Dead cells were excluded using
propidiumiodide.
Statistical analysis
Data are expressed as mean ± standard error of mean,
unless otherwise indicated. Experimental groups were
tested for statistically significant differences with the
Mann–Whitney U-test using SPSS 10.0 (SPSS Inc, Chi-
cago, IL, USA).
Results
Depletion of CD25-expressing cells exacerbates antigen-
induced arthritis
Mice were injected intraperitoneally with 0.5 mg anti-CD25
(PC61) 4 and 2 days before induction of arthritis (i.e. 19
and 17 days after first immunization). Depletion of CD25-
expressing cells was confirmed using FACS at the time of
AIA induction (day 0) using an antibody that recognizes a
different epitope on the CD25 molecule. In the PC61-Arthritis Research & Therapy    Vol 7 No 2    Frey et al.
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treated group there was a 70.9 ± 11.4% (n = 3) reduction
in CD4+CD25+ cells in the spleens as compared with con-
trol mice injected with rat IgG (Fig. 1). Of note, the anti-
CD25 treatment almost completely depleted cells with high
expression of CD25, which are considered Treg cells, in
contrast to CD4+ T cells with low or intermediate levels of
CD25 expression.
After intra-articular antigen injection, knee joint swelling of
the CD25-depleted mice was significantly greater from day
3 onward than in the control group injected with rat IgG
(Fig. 2a). Histological examination of knee joint sections 14
days after AIA induction revealed increased hyperplasia
and infiltration of the synovial membrane, as well as
increased articular damage in those animals (Fig. 2b–d). In
summary, this indicates a marked exacerbation of AIA by
depletion of CD25-expressing cells.
Increased cellular and humoral immune responsiveness 
in CD25-depleted mice
To assess how in vivo cellular immune responses against
mBSA are influenced by depletion of CD25-expressing
cells, delayed-type hypersensitivity (DTH) reaction against
the same antigen was tested by intradermal injection of
mBSA into the ears of mice at day 7 after induction of AIA.
Anti-CD25 treated mice mounted a significantly stronger
DTH response than did rat IgG-treated controls (Fig. 3a).
For analysis of the cellular immune responses ex vivo,
draining lymph node cells of arthritic animals were har-
vested 14 days after AIA induction, restimulated with
mBSA, and analyzed for proliferative response and
cytokine production. As expected from the increased DTH
reaction, the proliferative response to mBSA was signifi-
cantly increased in cells from CD25-depleted mice as com-
pared with that in rat IgG-treated controls (Fig. 3b).
Importantly, even without antigenic stimulation the lymph
node cells from CD25-depleted mice proliferated fourfold
as much as cells from mice treated with control IgG. These
data imply that a substantial proportion of the T-cell com-
partment is still activated 14 days after intra-articular anti-
gen challenge in the absence of Treg cells.
Compatible with these findings is that the production of
cytokines in response to mBSA was greater in CD25-
depleted mice. Importantly, both T-helper-1 (IFN-γ) and T-
helper-2 (IL-4) responses were aggravated by depletion of
Treg cells, indicating that both types of response are subject
to suppression by Treg cells (Fig. 3c). Again, cytokine secre-
tion from Treg-depleted animals was increased even without
antigenic stimulus. In accordance with this, serum levels of
IgG directed against mBSA as well as levels of the carti-
lage-specific autoantigens collagen type I, collagen type II
and proteoglycans, were found to be increased in CD25-
depleted mice (Fig. 3d).
Taken together, these data clearly demonstrate that
CD4+CD25+ Treg cells regulate the severity of arthritis by
limiting the cellular and humoral immune responses against
the inducing antigen mBSA as w e l l  a s  s o m e  a r t h r i t i s -
related autoantigens.
Transfer of CD4+CD25+ cells
To further characterize the suppressive potential of
CD4+CD25+ Treg cells, we performed cell transfer studies.
In a first set of experiments we transferred Treg cells freshly
isolated from naive (Fig. 4a) or mBSA/CFA immunized (Fig.
4b) mice into mBSA-immunized recipients at the time of
intra-articular antigen challenge (day 0). With this protocol,
a slight decrease in the severity of clinical arthritis (knee
joint swelling) could be induced. Accordingly, the histolog-
ical severity of AIA was also found to be reduced, albeit not
statistically significantly (Fig. 4a, b).
It is known that Treg cells must be activated via their T-cell
receptor to exert their suppressive function. Because we
were unable to use antigen-specific (i.e. T-cell receptor
transgenic) Treg  cells, we opted to pre-activate the
CD4+CD25+ cells by in vitro culture in the presence of anti-
CD3, anti-CD28 and IL-2 in order to increase their sup-
pressive potential. Transfer of 1 × 106 pre-activated cells
significantly suppressed both knee joint swelling and histo-
logical arthritis score (Fig. 4c). This effective suppression of
AIA development was a consistent finding in different
experiments, even with the use of lower cell numbers (for
instance 2 × 105 cells; data not shown).
Figure 1
Depletion of CD25-expressing cells by anti-CD25 treatment Depletion of CD25-expressing cells by anti-CD25 treatment. Mice 
immunized with methylated bovine serum albumin (mBSA) were 
injected intraperitoneally with 0.5 mg PC61 (anti-CD25) or rat IgG as 
control 4 and 2 days before arthritis induction. Representative example 
for flow-cytometric assessment of depletion in spleen cells, using a 
non-cross-reactive anti-CD25 antibody (7D4) at the time of arthritis 
induction (day 0).Available online http://arthritis-research.com/content/7/2/R291
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In the next step, we attempted to cure established arthritis
by transfer of Treg cells. Surprisingly, 1 × 106 pre-activated
CD4+CD25+ cells had no influence on either knee joint
swelling or histological arthritis score when transferred at
day 1 (Fig. 5a) or day 7 (Fig. 5b) after induction of arthritis.
Also, the transfer of 1 × 106 pre-activated αEβ7-expressing
Treg cells, which are highly effective in preventing AIA [10],
had no effect on disease at this time point (Fig. 5c).
Taken together, our data demonstrate that Treg cells can
inhibit arthritis development when transferred at the time of
arthritis induction. However, we were unable to demon-
strate any therapeutic effect of Treg cell transfer (in numbers
that are effective in prevention) when performed after dis-
ease onset.
Transferred CD4+CD25+ Treg cells do not suppress 
humoral or cellular immune responses
Because CD25-depletion caused a substantial increase in
both cellular and humoral immunoreactivity against mBSA,
we examined whether transfer of CD4+CD25+ Treg cells
can suppress these responses. Neither DTH reactivity
against mBSA (analyzed 7 days after AIA induction; Fig.
6a) nor mBSA-induced proliferation (Fig. 6b) and cytokine
production by draining lymph node cells (Fig. 6c) at day 14
after induction of AIA were found to be suppressed in the
recipients of 1 × 106  pre-activated CD4+CD25+  cells.
Thus, transfer of Treg cells into immunized animals does not
eliminate or induce functional modification to the previously
primed mBSA-specific immune response. In contrast,
transfer of CD4+CD25- cells did significantly enhance the
proliferation as well as the cytokine production in the recip-
ients. Accordingly, serum levels of IgG directed against
mBSA and the cartilage-specific autoantigens collagen
type I and type II, and proteoglycans were also not
Figure 2
Clinical and histological severity of antigen-induced arthritis (AIA) in CD25-depleted mice Clinical and histological severity of antigen-induced arthritis (AIA) in CD25-depleted mice. (a) Knee joint swelling (difference in mediolateral joint 
diameters of arthritic minus nonarthritic knee joints) during the time course of arthritis was higher in CD25-depleted mice. (b) Haematoxylin and 
eosin stained frontal knee joint sections were scored on a 0–3 point scale at day 14 of AIA for each of the following: severity of synovial hyperplasia, 
cellular infiltration, cartilage destruction and pannus formation. A score for inflammatory changes (Inf) was calculated by adding the points for syno-
vial hyperplasia and infiltration, and for joint destruction (Dest) by adding the points for cartilage damage and pannus formation. Total arthritis score 
(Score) was calculated by adding scores for inflammatory changes and joint destruction, giving a maximal AIA score of 12 points. Representative 
photomicrographs of (c) a control (rat IgG-injected) and (d) a knee joint from an anti-CD25-treated mouse. Ten animals were included in each group 
in two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, versus control.Arthritis Research & Therapy    Vol 7 No 2    Frey et al.
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significantly diminished in Treg cell recipients compared
with the saline-treated control group. Recipients of
CD4+CD25- cells had higher levels of IgGs (Fig. 6d).
Homing properties of CD4+CD25+ Treg cells
Because the mechanism of suppression of Treg cells in vitro
is cell contact dependent, localization of cells might be
important for their regulatory activity. Therefore, we
investigated the migration behaviour of CD4+CD25+ and
CD4+CD25- cells  in vivo. For these experiments CD4+
cells were enriched by negative selection and sorted by
FACS into CD4+CD25+ and CD4+CD25- populations with
preferential use of F(ab)-fragments or antibodies, which do
not interfere with migration in vivo. Cells were labelled with
111In and injected intravenously into AIA mice 7 days after
Figure 3
Analysis of in vivo and ex vivo immune responses in CD25-depleted  mice Analysis of in vivo and ex vivo immune responses in CD25-depleted 
mice. (a) In vivo delayed-type hypersensitivity (DTH) response against 
methylated bovine serum albumin (mBSA) as a marker for cellular 
immune response was measured as the increase in ear thickness after 
intradermal antigen challenge on day 7 of antigen-induced arthritis 
(AIA). (b) Proliferation, measured as [3H]thymidine incorporation of 
unstimulated (unst) or mBSA-stimulated (mBSA) draining lymph node 
cells at day 14 of AIA. (c) Cytokine production was measured with 
ELISPOT. (d) Serum levels of IgG against mBSA, collagen type I, colla-
gen type II and cartilage proteoglycans were measured using ELISA 
after 14 days of AIA. Proliferation, DTH reaction and serum IgG titres 
were tested in 10 animals per group; cytokine production was meas-
ured in six animals per group. Data are from one out of two similar 
experiments. *P < 0.05, **P < 0.01, ***P < 0.001, versus control.
Figure 4
Modulation of antigen-induced arthritis (AIA) by transfer of regulatory T  cells (Treg cells) Modulation of antigen-induced arthritis (AIA) by transfer of regulatory T 
cells (Treg cells). Amelioration of clinical and histological severity of AIA 
by transfer of 2 × 106 CD4+CD25+ cells freshly isolated from (a) naive 
or (b) immunized mice at the time of AIA induction (day 0; n = 6 per 
group). (c) Transfer of 1 × 106 in vitro pre-activated cells at the time of 
AIA induction (n = 6). #P < 0.05, ##P < 0.01 for CD4+CD25+ versus 
CD4+CD25-; +P < 0.05, ++P < 0.01 for CD4+CD25+ versus phos-
phate-buffered saline. Dest, joint destruction; Inf, inflammatory changes; 
Score; total arthritis scoreAvailable online http://arthritis-research.com/content/7/2/R291
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induction of arthritis. After 24 hours radioactivity was meas-
ured in different organs.
Compared with CD4+CD25- cells, CD4+CD25+ Treg cells
were less abundant in secondary lymphoid organs such as
lymph nodes and spleen. Thus, CD4+CD25+ cells recircu-
late through these organs less than do CD4+CD25- cells.
In the liver, more radioactivity was recovered in recipients
of CD4+CD25+ cells as compared with CD4+CD25- cells.
Importantly, CD4+CD25+ cells also had a significantly bet-
ter capacity to enter the inflamed joint than did CD4+CD25-
cells (Fig. 7a). The level of radioactivity detected in the
arthritic joints was low but similar to levels found in transfer
experiments with effector T cells [18]. As a control, some
mice were injected with CFSE-labelled cells. FACS analy-
sis of the secondary lymphoid organs revealed the pres-
ence of viable cells 24 hours after transfer and excluded the
Figure 5
Transfer of regulatory T cells (Treg cells) cannot cure established  arthritis Transfer of regulatory T cells (Treg cells) cannot cure established arthri-
tis. Pre-activated CD4+CD25+ cells (1 × 106) were transferred on (a) 
day 1 or (b) day 7 of antigen-induced arthritis (AIA). Arthritis severity 
was monitored by measurement of knee joint swelling and by histologi-
cal assessment 14 days after cell transfer (n = 6–7 per group). (c) 
Also, 1 × 106 pre-activated αEβ7-expressing Treg cells have no curative 
effect in AIA (n = 8 per group).
Figure 6
There is no suppression of cellular or humoral methylated bovine serum  albumin (mBSA)-specific immunity with transfer of Treg cells There is no suppression of cellular or humoral methylated bovine serum 
albumin (mBSA)-specific immunity with transfer of Treg cells. Pre-acti-
vated CD4+CD25+ cells (1 × 106) were transferred at the time of anti-
gen-induced arthritis (AIA) induction. (a) Delayed-type hypersensitivity 
(DTH) reactivity against mBSA in vivo was tested 7 days later by an 
intradermal antigen challenge into the ears. (b) Antigen-specific prolif-
eration ([3H]thymidine incorporation) and (c) cytokine production (ELIS-
POT) of draining lymph node cells was measured 14 days after AIA 
induction. (d) Serum levels of IgG against mBSA, collagen type I, colla-
gen type II and cartilage proteoglycans were measured with ELISA after 
14 days of AIA. Proliferation, DTH reaction, cytokine production, and 
serum IgG titres were tested in six animals per group. #P < 0.05 for 
CD4+CD25+ versus CD4+CD25-; *P < 0.05 for CD4+CD25- versus 
phosphate-buffered saline.Arthritis Research & Therapy    Vol 7 No 2    Frey et al.
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possibility that the difference in migration pattern is due to
leakage of radioactivity (Fig. 7b). The migration behaviour
of CD4+CD25+ Treg cells does reflect their more activated
phenotype, and their ability to enter inflamed joints makes it
possible that they act directly at the site of inflammation.
Discussion
Our findings provide clear evidence that CD4+CD25+ Treg
cells are critical for regulating the severity of AIA in mice.
We showed this by manipulating the Treg cell numbers
using two different approaches: depletion of CD25-
expressing cells and transfer of purified CD4+CD25+ Treg
cells. It is important to stress that we depleted CD25-
expressing cells in the interval between immunization and
AIA induction, because CD25-depletion before immuniza-
tion profoundly increases the resulting humoral and cellular
immune responses [3,12]. These data are consistent with
studies conducted in collagen-induced arthritis; however,
in these experiments CD25-expressing cells were depleted
before immunization with collagen type II, and the resulting
more severe arthritis could be interpreted as the result of
stronger immunization state [12]. With our experimental
design, we were able to examine the effect of Treg cells in
ongoing joint inflammation directly. Because CD25 is also
expressed on activated conventional T cells, it could be
assumed that injection of an anti-CD25 antibody would
deplete not only Treg cells but also effector T cells, but the
exacerbated AIA in CD25-depleted mice argues against
such a depletion of effector T cells. Accordingly, in control
experiments lymph node cells from CD25-depleted mice
isolated at the time of induction of AIA were able to mount
a similar anti-mBSA response in vitro as compared with
control mice (data not shown). Furthermore, CD4+CD25+
cells isolated from immunized donors can suppress devel-
opment of AIA (Fig. 4b). Taken together, these data imply
that the CD25+ compartment in immunized mice largely
consists of Treg cells.
AIA induction in CD25-depleted mice resulted in a much
more severe arthritis in the acute and chronic stages of dis-
ease. We recently showed, with the use of a depleting anti-
CD4 antibody, that this acute stage of AIA is already under
the control of T cells [15]. Nevertheless, early AIA is domi-
nated by cells of the innate immune system [19], and the
exacerbation of arthritis in CD25-depleted mice could be
due to a lack of suppression of these cells by Treg cells. In
accordance with this view, CD4+CD25+ Treg cells are able
to suppress innate immune cells in a model of bacteria-
induced colitis [20].
In later stages exacerbated arthritis in CD25-depleted mice
is accompanied by increased mBSA-specific proliferation
and IgG production. This enhanced responsiveness
emerged during arthritis development and is due to sus-
tained T cell activation. Such prolonged T cell activation in
the absence of CD4+CD25+ cells has also been described
in other disease models [21] and is probably the cause of
the increased AIA severity. Moreover, the PC61 antibody
used in our study has a half-life of approximately 3 weeks in
vivo (Sutmuller R, personal communication), which makes
it possible that Treg cell function is not only impaired by
depletion but also by blockade of IL-2 binding to CD25 by
the PC61 antibody. IL-2 or IL-2 signalling via CD25 has
been shown to be critical to the regulatory action of Treg
cells [22,23]. Also, activation-induced cell death of patho-
genic T cells, which is regulated by IL-2, could be impaired
Figure 7
Migration behaviour of regulatory T cells (Treg cells) Migration behaviour of regulatory T cells (Treg cells). (a) CD4+CD25+ 
and CD4+CD25- cells were purified by fluorescence-activated cell sort-
ing (FACS) and labelled with 111In. Cells (1 × 106) were injected intra-
venously into antigen-induced arthritis (AIA) mice at day 7. After 24 
hours radioactivity in isolated organs and the rest of the body was 
determined using a γ-counter. Thereafter, the total radioactivity recov-
ered per animal was calculated by adding the counts of the organs and 
the rest of the body. (a) The proportion of radioactivity found in the iso-
lated organs is shown here as a percentage of total recovered radioac-
tivity (n = 6; mean ± standard error of the mean; one representative out 
of two independent experiments; **P < 0.01). (b) FACS-purified cells 
were labelled with 5,6-carboxyfluorescein diacetate succinimidyl ester 
(CFSE) and injected intravenously. After 24 hours single-cell suspen-
sions from draining lymph node (dLN), nondraining peripheral lymph 
node (pLN), mesenteric lymph node (mLN), spleen and peripheral 
blood lymphocytes (PBL) were analyzed by FACS. The percentage of 
CFSE+ cells of the total CD4+ cells was measured. Histogram plots are 
gated on CD4+ cells after propidium–iodide exclusion of dead cells (n 
= 3 per group). Higher numbers of CFSEhigh cells are found in the sec-
ondary lymphoid organs in the recipients of CD4+CD25- cells.Available online http://arthritis-research.com/content/7/2/R291
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by withdrawal of IL-2 signalling and therefore contribute to
the observed high levels of cellular immune responses in
our study [24].
The fact that depletion of CD4+CD25+ Treg cells enhances
the immune response against the foreign antigen mBSA
clearly demonstrates that their suppressive effect is not
strictly limited to autoreactive T cells. Taking into consider-
ation that Treg cells are also critically involved in the control
of immune responses against pathogens [25,26], their
physiological function is not just to prevent autoimmunity
but also to control the extent of inflammatory reactions in
order to prevent tissue damage to the host. Further support
for the influence of CD4+CD25+ Treg cells on arthritis devel-
opment came from the transfer experiments. When trans-
ferred at the time of induction of AIA, CD4+CD25+ cells
were able to ameliorate ongoing disease. Analysis of the
recipients did not reveal a remarkable long-lasting suppres-
sion of systemic mBSA-specific immune reactions. Thus,
prevention of AIA appears to be possible without inducing
anergy or abrogating previously induced T-cell effector
functions [27]. In contrast to this, transferred CD4+CD25-
cells significantly enhance cell-mediated and humoral
immune responses.
Furthermore, the homing data presented here demonstrate
that CD4+CD25+ cells can migrate into the arthritic knee
joint. Functional Treg  cells have repeatedly been found
within such effector sites and/or draining lymph nodes, for
instance in tolerated allografts [28], in Langerhans islets
and pancreatic lymph nodes in inflammation-induced dia-
betes [29], in chronically inflamed skin in a Leishmania
infection model [30], and in the mucosa and mesenteric
lymph nodes in inflammatory colitis in severe combined
immunodeficient (SCID) mice [31]. Interestingly, two
recent papers [32,33] reported an accumulation of func-
tional Treg cells in the inflamed joints of patients with RA,
juvenile arthritis and other rheumatic diseases.
It is most likely that the transferred CD4+CD25+ Treg cells
act in the draining lymph node as well as in the inflamed tis-
sue. Within such a scenario, it could be possible that Treg
cells inhibit the activation of effector T cells and their sub-
sequent migration to the joints. Such a mechanism was
recently speculated in modulation of virally induced immun-
opathology by T cells [26].
Huehn and colleagues [11] recently demonstrated that
CD4+CD25+ Treg cells can be divided into subsets based
on the expression of the integrin αEβ7. Moreover, this
marker identifies CD25- Treg cells [34]. Both αEβ7-express-
ing subsets had better capacity to reach the inflamed joint
and to prevent arthritis in the AIA model, as compared with
αEβ7
- Treg cells [10]. Thus, suppression at the site of inflam-
mation is also an important part of the activity of Treg cells.
How this effect is mediated is unclear but an involvement of
IL-10 or transforming growth factor-β is possible
[20,35,36].
If these hypotheses are correct, then they could explain
why the transfer of Treg cells after arthritis induction is not
effective. On the one hand, transfer of Treg cells 24 hours
after intra-articular antigen challenge might be too late to
inhibit activation of effector T cells and their migration to the
joint. Indeed, T-cell activation is an early event in AIA
because CD4+ T cell depletion ameliorates the acute stage
of the model [15]. On the other hand, it could be possible
that the suppressive function of regulatory T cells is
switched off under the inflammatory conditions present in
the inflamed tissue by factors such as IL-6 or
glucocorticoid-induced tumor necrosis factor family-related
gene (GITR) and GITR-ligand interactions, abrogating the
suppressive effect of Treg cells [37]. With this in mind, it
could be interesting to investigate whether the accumu-
lated Treg cells in patients with arthritis function properly in
vivo and whether these patients could really benefit from a
therapeutic enhancement of Treg function, as suggested by
some enthusiastic investigators in this field.
In this regard, data on the curative effects of Treg cells in
experimental disease models are conflicting. To best of our
knowledge, a curative effect of CD4+CD25+ Treg cells has
only been demonstrated in the colitis model induced by
transfer of CD45RBhigh T cells into SCID mice [31,38]. In
contrast, other authors were unable to demonstrate such
an inhibitory effect of Treg cells on SCID colitis when they
were transferred 1 week after administration of pathogenic
CD45RBhigh T cells [39]. Because arthritis in the AIA model
has a hyperacute onset, it could be assumed that the time
window for an ameliorative effect of Treg cell transfer ends
very shortly after intra-articular injection of antigen. How-
ever, further studies on the role of Treg cells in other arthritis
models are clearly needed to clarify whether enhancement
in Treg cell function might be beneficial in experimental
arthritis and perhaps in human disease.
Conclusion
Our data show that Treg cells are critically involved in the
control of immune responses that are responsible for the
pathogenesis of chronic arthritis. Transfer of such cells can
modulate the severity of ongoing inflammatory arthritis but
they cannot suppress established disease. Thus, timing of
Treg cell transfer for therapeutic purposes is of considerable
importance.
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